In our current mini-series exploring emerging biotech companies with early pipelines and novel targets, we investigate some interesting approaches that are not common place. As large cap Pharmaland companies seem overly focused on hunting for the next checkpoint target, smaller biotechs are more nimbly coming up with some fresh ideas that might have solid merit down the road.
This is one of those such innovative companies.
What if there was a different approach where we can learn from the immune system’s response to a cancer? Sounds obvious and intuitive when put so baldly, yet few companies are actually doing that in practice.
What would such a process and pipeline look like?
Come and find out for yourselves – you may well be surprised because some ideas that seem crazy at first blush, could turn out to be rather useful indeed…
To learn more from our oncology coverage and get a heads up on insights emerging our latest analysis and commentary, subscribers can log-in or you can click to gain access to BSB Premium Content.
It’s time for an extended update on the neoantigen space now that we have new clinical data to look at and discuss. There are a variety of approaches being evaluated in the clinic now, from adenoviral vectors to cell therapies to vaccines.
Indeed, we haven’t covered Moderna Therapeutics before as they were rather quiet in preclinical mode, but now they have some initial clinical data in cancer patients, we thought it would be nice to explore the company’s progress, as well as look at where they’re headed with their mRNA platform.
In the hotseat today, we take a look at the latest developments in the neoantigen vaccine field in terms of oncology settings and have an engaging company interview in the spotlight as well.
To learn more and get a heads up on our latest oncology insights and thought leader interview, subscribers can log-in or you can click to gain access to BSB Premium Content.